Insulin Efsitora Alfa vs insulin icodec
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Efsitora Alfa · Onswik
Marketed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)
Result source: NCT05662332
insulin icodec · Awiqli
Marketed by Novo Nordisk
NCT04760626 · Phase 3 · completed
The study was randomized and actively controlled, but it was open-label, with 542 participants assigned to insulin icodec and 543 to once-daily basal insulin analogues. The primary HbA1c endpoint was met for non-inferiority, but HbA1c is a surrogate measure rather than a hard clinical or endoscopic endpoint, supporting a moderate evidence grade.
Next expected readout: October 2027 · NCT07747402 (registry estimate)
Reported efficacy
Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Change in Glycated Haemoglobin (HbA1c) (Week 0, Week 26): Insulin Icodec -0.84 Percentage (%) point (Standard Deviation 0.83) vs Insulin Glargine -0.58 Percentage (%) point (Standard Deviation 0.89) (met)
Result source: NCT06340854
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin Efsitora Alfa | insulin icodec |
|---|---|---|
| HbA1c, change | -1.3% vs -1.2%vs Insulin DegludecNCT0536205811 other results
| -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT0476062611 other results
|
| Body weight, change (kg) | 3.6 vs 3.5vs Insulin DegludecNCT053620586 other results
| 2.3 vs 1.8vs Insulin GlargineNCT0446088510 other results
|
| HbA1c below 7% | —Not reported | —Not posted · NCT05013229 |
| Fasting plasma glucose, change | —Not reported | -3.4 vs -3.3vs Insulin GlargineNCT044608859 other results
|
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05013229 |
HbA1c, change
- Insulin Efsitora Alfa
- -1.3% vs -1.2%vs Insulin DegludecNCT05362058
11 other results
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.0% vs -1% NCT05462756
- -1.3% vs -1.2% NCT05362058
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.4% vs -1.3% NCT05362058
- -1.0% vs -1% NCT05462756
- -0.6% vs -0.7% NCT03736785
- -0.6% vs -0.7% NCT03736785
- -1.2% vs -1.3% NCT04450394
- insulin icodec
- -1.7% vs -1.3%vs Once Daily Basal Insulin AnalogueNCT04760626
11 other results
- -1.6% vs -1.4% NCT04460885
- -0.8% vs -0.6% NCT06340854
- -1.6% vs -1.4% NCT04795531
- -0.9% vs -0.7% NCT04770532
- -1.2% vs -1.2% NCT04880850
- -1.3% vs -1.1% NCT03751657
- -0.5% vs -0.5% NCT03922750
- -0.8% vs -0.5% NCT03922750
- -1% vs -1.0% NCT03951805
- -1.2% vs -1.0% NCT03951805
- -1.4% vs -1.0% NCT03951805
Body weight, change (kg)
- Insulin Efsitora Alfa
- 3.6 vs 3.5vs Insulin DegludecNCT05362058
6 other results
- 3.9 vs 3.3 NCT05662332
- 2.3 vs 2.2 NCT05275400
- 3.2 vs 2.7 NCT05362058
- 2.7 vs 2.5 NCT05462756
- 1 vs 2 NCT03736785
- 1 vs 2 NCT03736785
- insulin icodec
- 2.3 vs 1.8vs Insulin GlargineNCT04460885
10 other results
- 2.0 vs 0.6 NCT06340854
- 2.8 vs 2.3 NCT04795531
- 1.4 vs -0.3 NCT04770532
- 2.7 vs 2.2 NCT04880850
- 1.5 vs 1.6 NCT03751657
- 1.3 vs 0.1 NCT03922750
- 0.6 vs 0.1 NCT03922750
- 0.9 vs 0.6 NCT03951805
- 1.1 vs 0.6 NCT03951805
- 1.3 vs 0.6 NCT03951805
HbA1c below 7%
- Insulin Efsitora Alfa
- —Not reported
- insulin icodec
- —Not posted · NCT05013229
Fasting plasma glucose, change
- Insulin Efsitora Alfa
- —Not reported
- insulin icodec
- -3.4 vs -3.3vs Insulin GlargineNCT04460885
9 other results
- -3.0 vs -3.0 NCT04795531
- -1.6 vs -1.6 NCT04770532
- -1.8 vs -1.6 NCT04880850
- -3.2 vs -3.0 NCT03751657
- -0.8 vs -0.6 NCT03922750
- -0.7 vs -0.6 NCT03922750
- -2.2 vs -2.3 NCT03951805
- -2.4 vs -2.3 NCT03951805
- -3.0 vs -2.3 NCT03951805
3-point MACE (% with event)
- Insulin Efsitora Alfa
- —Not reported
- insulin icodec
- —Not posted · NCT05013229
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Insulin Efsitora Alfa: 8 of 8 rows · insulin icodec: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin Efsitora Alfa Rows use multiple source trials | insulin icodec Rows use multiple source trials |
|---|---|---|
| Time Above Range absolute value · % of time | 29.66 vs 33.05 Insulin Degludec % of time @ 52wka NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 26.86 vs 32.27 Insulin Glargine % of time @ 52wka NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Time Below 54 mg/dL absolute value · percentage points | 0.33% (n=368) vs 0.28% (n=360) Insulin Degludec @ 26wkb,c NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 0.34% (n=238) vs 0.22% (n=239) Insulin Degludec @ 26wkb,c NCT04770532 · Phase 3 |
| Time Below Range absolute value · % of time | 0.36 vs 0.22 Insulin Degludec % of time @ 26wk500 U/mLa,d NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 1 other source trial6.84 vs 5.25 Insulin Glargine % of time @ 26wk NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 | 0.27 vs 0.21 Insulin Glargine % of time @ 52wka,d NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Time in Range absolute value · percentage points | 64.27% (n=387) vs 61.18% (n=381) Insulin Degludec @ 52wka NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 | 71.94% (n=439) vs 66.9% (n=440) Insulin Glargine @ 52wka NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 |
| Dropout rate | 9.5%500 U/mLe NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results5.4% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 8.8%Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 12.6%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 12.9%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | 8.3%f NCT04760626 · Phase 3 show 14 more results3.7% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 2% NCT04795531 · Phase 3 1.1% NCT04770532 · Phase 3 5.5% NCT04880850 · Phase 3 36.5%Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 2% NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 2.4% NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.1%500 U/mLe NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results0.6% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 0.7%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 0.8%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | —f NCT04760626 · Phase 3 show 14 more results— NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT04795531 · Phase 3 — NCT04770532 · Phase 3 — NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination —Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination — NCT05823948 · Phase 3 · registry result, not featured evidence 1.9%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence — NCT03751657 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.7%500 U/mLe NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results8.8% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.7%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 7.1%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 5.2%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 6.1%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence | 8.3%f NCT04760626 · Phase 3 show 14 more results13% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 7.8% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 5.1% NCT04795531 · Phase 3 8.4% NCT04770532 · Phase 3 7.6% NCT04880850 · Phase 3 —Insulin Icodec + Semaglutide NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.2%Insulin Icodec + Semaglutide: Trea NCT05813912 · Phase 3 · registry result, not featured evidence · combination 3.9% NCT05823948 · Phase 3 · registry result, not featured evidence 3.7%Insulin 287 (With 100% Loading Dos NCT03922750 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Without Loading Dose) NCT03922750 · Phase 2 · registry result, not featured evidence 1.6% NCT03751657 · Phase 2 · registry result, not featured evidence 5.9%Insulin 287 (Titration Algorithm A NCT03951805 · Phase 2 · registry result, not featured evidence 2%Insulin 287 (Titration Algorithm B NCT03951805 · Phase 2 · registry result, not featured evidence 0%Insulin 287 (Titration Algorithm C NCT03951805 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 500 U/mLe covid-19 10.7% nasopharyngitis 9.2% dose calculation error 6.4% NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 7 more resultsnasopharyngitis 9.2% covid-19 7.9% upper respiratory tract infection 7.9% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 4.7% arthralgia 2.3% diarrhoea 2.3% NCT04450394 · Phase 2 · registry result, not featured evidence abdominal discomfort 7.1% anaemia 7.1% chest pain 7.1% NCT04450394 · Phase 2 · registry result, not featured evidence diarrhoea 6.7% upper respiratory tract infection 5.9% cough 0.7% NCT03736785 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 10.6% diarrhoea 6.1% dizziness 5.3% NCT03736785 · Phase 2 · registry result, not featured evidence | show 13 more resultscovid-19 17.7% back pain 8.1% diarrhoea 7.9% NCT04460885 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 nasopharyngitis 13.6% diarrhoea 5.3% diabetic retinopathy 2.9% NCT06340854 · Phase 3 · combination · Type 2 Diabetes · phase 3 nausea 19.1% vomiting 8.5% upper respiratory tract infection 7.4% NCT05813912 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 13.7% covid-19 9.8% back pain 7.8% NCT05823948 · Phase 3 · registry result, not featured evidence nasopharyngitis 14.8% medical device site haemorrhage 9.3% headache 5.6% NCT03922750 · Phase 2 · registry result, not featured evidence nasopharyngitis 14% hypertension 6% influenza 6% NCT03922750 · Phase 2 · registry result, not featured evidence headache 11.2% nasopharyngitis 8% upper respiratory tract infection 5.6% NCT03751657 · Phase 2 · registry result, not featured evidence back pain 9.8% nasopharyngitis 9.8% headache 0% NCT03951805 · Phase 2 · registry result, not featured evidence nasopharyngitis 13.7% headache 5.9% back pain 3.9% NCT03951805 · Phase 2 · registry result, not featured evidence headache 9.6% nasopharyngitis 3.8% back pain 1.9% NCT03951805 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation context differs: baseline_threshold differs (bmi<=40, hba1c<=11, hba1c>=7 versus bmi<=45); prior_therapy differs (naive versus experienced).
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 26 weeks.
- ePopulation comparability has not been reviewed for 4 of these studies.
- fPopulation comparability has not been reviewed for 13 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin Efsitora Alfa
show 4 more results
show 3 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
+ 1 further endpoint in the CSV export.
insulin icodec
show 9 more results
show 3 more results
show 3 more results
show 3 more results
show 5 more results
show 1 more result
+ 3 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · insulin icodec's landscape